Von Willebrand Disease Clinical Trial
— MEVA-3Official title:
Protocol for the Determination of Menstrual Blood Losses in Women Affected by Congenital Bleeding Disorders
Verified date | December 2010 |
Source | University of L'Aquila |
Contact | n/a |
Is FDA regulated | No |
Health authority | Italy: The Italian Medicines Agency |
Study type | Observational |
Menorrhagia is the term used to define excessive menstrual blood losses, as often based on a
subjective judgment of women. Many arbitrary values, expressed in milliliters of blood, have
been proposed to define this symptom: 60 on each cycle has also been confirmed in our
preliminary study on 87 healthy women. The quantitative determination of menstrual blood
losses is nevertheless rarely performed, only in research settings. Although menorrhagia is
a quite frequent symptom in healthy women apparently haemostatically competent in the
fertile age (20-30%), its incidence becomes very high in women affected by congenital
coagulation factors deficiency and (50-62.9%) inherited platelet defects, e.g. Glanzmann's
Thromboasthenia (GT); also in von Willebrand Disease the bleeding symptom "menorrhagia" has
an high prevalence (60-75%)(8); for GT an incidence of 90% has been reported.
This explains the need for a study focused on the evaluation of menorrhagia in CBDs,
addressed to answer to the following, still unsolved questions:
1. Definition of the entity of menstrual blood losses in women affected by CBDs
2. Elaboration of specific treatment schedules for each type of CBD
3. Impact of different specific treatment schedules on kinetic and entity of menstrual
losses (how does treatment modify losses?).
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 2011 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1. Age between 18 and 45 years; 2. Ascertained diagnosis of one of the following inherited bleeding disorders: 1. Von Willebrand Disease type 1, 2, 3 severe and moderate (VWF:RCo < 30 %),as diagnosed following Italian guidelines [4] 2. Glanzmann Thromboasthenia 3. Congenital Coagulation Factor VII, II or X deficiency 4. A and B Haemophilia Carriers (Factor VIII and IX <25%); 3. Bleeding Severity score > 2 4. Signing the consent form. Exclusion Criteria: 1. Under continuous anti-hemorrhagic prophylaxis 2. Affected by an active cancer or anti-phospholipid antibodies syndrome 3. History of liver, kidney or endocrine disorders 4. Submucous uterine fibroids, uterine polyps or malignancy 5. Use of oral contraceptives or intrauterine devices in the past three months 6. Treatment with non-steroidal anti-inflammatory drugs |
Observational Model: Case-Crossover, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Italy | Thrombosis and Hemostasis Center-University of L'Aquila | L'Aquila | |
Italy | Hematology Department-University of Palermo | Palermo | |
Italy | IRCCS "Casa Sollievo della Sofferenza"-Thrombosis and Haemostasis Center | San Giovanni Rotondo | FG |
Lead Sponsor | Collaborator |
---|---|
University of L'Aquila |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quantitative determination of menstrual blood losses | Quantitative determination of menstrual blood losses in women in the fertile age( between 18 and 45 years) affected by an inherited haemorrhagic disorder diagnosed on the basis of the current International Standard Criteria.This study is preliminary to the evaluation of the efficacy of each | 1 year | No |
Secondary | kinetic definition of menses | Kinetic definition of menses (hours and days of flow) with and without specific treatment | monthly | No |
Secondary | Influence of treatment on menstrual blood losses | To define the influence of substitutive therapies on menstrual losses | monthly | No |
Secondary | treatment schedule evaluation | Elaboration of specific treatment schedules for each type of CBD, as evaluated by QUEM | monthly | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01651468 -
The Effect of the Nutraceutical "Hemofix" on the Coagulation System
|
N/A | |
Active, not recruiting |
NCT00555555 -
Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients
|
Phase 4 | |
Terminated |
NCT00178542 -
Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle
|
N/A | |
Completed |
NCT02552576 -
Study of Voncento® in Subjects With Von Willebrand Disease
|
Phase 4 | |
Recruiting |
NCT02869074 -
Molecular and Clinical Profile of Von Willebrand Disease in Spain
|
||
Completed |
NCT01602419 -
Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease
|
||
Completed |
NCT01224808 -
Extension Study of Biostate in Subjects With Von Willebrand Disease
|
Phase 3 | |
Withdrawn |
NCT00694785 -
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B
|
Phase 2 | |
Completed |
NCT00805051 -
Acquired Von Willebrand Syndrome in Severe Aortic Stenosis
|
N/A | |
Completed |
NCT02246881 -
A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.
|
Phase 3 | |
Completed |
NCT00168090 -
Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)
|
Phase 4 | |
Completed |
NCT04657887 -
Registry of Patients With Von WilLEbrand Disease Treated With Voncento®
|
||
Withdrawn |
NCT00630448 -
Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)
|
N/A | |
Terminated |
NCT00387192 -
A Study With OPTIVATE® in People With Von Willebrand Disease
|
Phase 3 | |
Completed |
NCT02973087 -
rVWF IN PROPHYLAXIS
|
Phase 3 | |
Completed |
NCT01410227 -
Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)
|
Phase 3 | |
Completed |
NCT01949220 -
Willebrand International Non-interventional Global Surveillance
|
||
Completed |
NCT01589848 -
Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador
|
N/A | |
Completed |
NCT00941616 -
Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease
|
Phase 2/Phase 3 | |
Completed |
NCT00557908 -
The Von Willebrand Disease (VWD) International Prophylaxis Study
|
N/A |